首页> 美国卫生研究院文献>Pharmaceutics >Temperature Dependence of the Complexation Mechanism of Celecoxib and Hydroxyl-β-cyclodextrin in Aqueous Solution
【2h】

Temperature Dependence of the Complexation Mechanism of Celecoxib and Hydroxyl-β-cyclodextrin in Aqueous Solution

机译:塞来昔布与羟基-β-环糊精在水溶液中络合机理的温度依赖性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Hydroxypropyl-β-cyclodextrin (HP-β-CD) is commonly used as a complexation reagent to solubilize compounds with poor aqueous solubility to improve in vivo dosing. However, the degree of solubility enhancement was often limited by the formation of only a 1:1 complex and a low complexation constant (K). Such a limitation can be significantly improved by the formation of 1:2 complexes in some cases. Despite the understanding of the solubility advantage of the formation of the 1:2 complexes, there is no systematic understanding that could drive for the formation of 1:2 complexes. Thus, in most cases, the formation of 1:2 complexes was limited by observation bases. In this study, we pioneer the usages of molecular dynamics (MD) simulation to understand the phenomena of a model drug of celecoxib (CCB) and HP-β-CD. It has been reported that celecoxib (CCB) forms 1:1 complexes with cyclodextrin in solution; however, some data suggest the existence of a 1:2 complex. The simulation results suggest that a transition state of CCB and HP-β-CD may exit at a higher temperature of CCB and HP-β-CD; a model drug, such as celecoxib (CCB), that is known to form 1:1 complexes can achieve a higher degree of complexation (1:2) and obtain much improved solubility when the same amount of cyclodextrin was used and demonstrated in vitro. The simulation results of CCB and HP-β-CD could be a model system that may provide important insights into the inclusion mechanism.
机译:羟丙基-β-环糊精(HP-β-CD)通常用作络合剂,以溶解水溶性差的化合物以改善体内剂量。但是,溶解度提高的程度通常仅受1:1络合物和低络合常数(K)的限制。在某些情况下,通过形成1:2的复合物可以大大改善这种限制。尽管了解了1:2配合物形成的溶解度优势,但没有系统的理解可以推动1:2配合物的形成。因此,在大多数情况下,1:2配合物的形成受到观察基地的限制。在这项研究中,我们率先使用分子动力学(MD)模拟来了解塞来昔布(CCB)和HP-β-CD模型药物的现象。据报道,塞来昔布(CCB)与环糊精在溶液中形成1:1的复合物。但是,一些数据表明存在1:2的复合物。仿真结果表明,CCB和HP-β-CD的过渡态可能会在CCB和HP-β-CD的较高温度下退出。当使用相同量的环糊精并在体外证明时,已知可以形成1:1配合物的模型药物(例如celecoxib(CCB))可以获得更高的配合度(1:2),并且溶解度大大提高。 CCB和HP-β-CD的模拟结果可能是一个模型系统,可以为包涵机制提供重要见解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号